Mauna Kea Technologies' Cellvizio platform identified Barrett's esophagus in more than twice as many patients as the current diagnostic standard, according to the results of a multicenter prospective trial presented April 12 at the 2018 World Congress of Endoscopic Surgery in Seattle.
Here are five things to know.
1. Cellvizio is a multidisciplinary probe-based confocal laser endomicroscopy platform.
2. The study included 172 patients scheduled for a Barrett's esophagus screening or surveillance endoscopy. Random four quadrant biopsy performed under high-definition white-light endoscopy, also known as the Seattle protocol, was compared to Cellvizio pCLE and interpreted in real time and after the procedure.
3. Cellvizio identified Barrett's esophagus in 99 patients; the Seattle protocol identified 46 patients.
4. According to Paul A. Severson, MD, Co-Director of the Minnesota Reflux and Heartburn Center in Crosby, monitoring gastroesophageal reflux disease is crucial because Barrett's esophagus is associated with a heightened risk of developing esophageal cancer. The Seattle protocol is the current diagnostic standard, but it is often poorly followed and has low diagnostic yield, Dr. Severson said.
5. Cellvizio is Mauna Kea's flagship product. Mauna Kea received clearance to sell Cellvizio in more than 40 countries, including the U.S., Europe, Japan, China, South Korea, Canada, Brazil and Mexico.
More articles on gastroenterology:
AI tool successfully diagnoses CRC in real-world study
70% of minimally invasive esophagectomy patients back to work 1 year postoperatively: 6 insights
Sen. John McCain in stable condition after intestinal surgery — 4 insights